Justin Briggs work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
Justin Briggs personal email
- Valid
Justin Briggs phone numbers
Justin Briggs is a scientist, entrepreneur, and investor who lives to build companies at the nexus of biology, chemistry, and engineering.Justin leads Corporate Development for Zafrens, the world’s highest throughout functional drug discovery technology. Justin also serves as Biologist and Operating Partner at Prime Movers Lab, a leading investor of breakthrough science. PML invests in scientific founders leading companies with the potential to impact billions of lives. Boards: Justin serves as a member of the board of directors at Morphoceuticals, LyGenesis, Iridia, and previously served on the Boards of Gilgamesh, Elevian, Dimension Inx, Zafrens and Iviva Medical (acquired, United Tx).Over the last 20 years Justin has developed advanced technologies and companies around them for the life science and deep tech industries. Justin has developed new medicines and medical devices from the bench through phase 2 clinical trials in various diseases areas with small molecules, antibodies, oligos and vectored vaccines across ten regulatory jurisdictions across four continents. Justin has been involved as a founder, investor, advisor or team member for more than a dozen biotech, nanotech and software companies. Prior to PML, Justin invested as founding partner at TomorrowScale Ventures, a seed-stage venture firm. Before that, Justin served as a Venture Partner at Deep Science Ventures, a venture laboratory building optimal scientific ventures from scratch based in London, UK. Justin supported their portfolio of leading early-stage deep tech startups founded through the DSV program and located throughout the world.As an operator Justin helped build and oversee the portfolio of novel antibody therapeutics designed in silico and de novo (from scratch) against difficult targets by the brilliant team at Antiverse. Prior to Antiverse, Justin served as Senior Director of Drug Development at Tetherex Pharma (now Moat Bio). Tetherex is a clinical-stage biopharma company developing novel biologics for the treatment of inflammatory, oncologic, and infectious diseases.In his early career, Justin served as VP of Business Development and Operations at Accele BioPharma and Associate at Accele Venture Partners, a biotech accelerator and VC fund. Justin also founded SnapLab Technologies (lab automation and machine vision for oil and gas surface analysis) and productivity software company Chorus Labs (acquired 2015; Creators of Baton, email+kanban+chat).
-
Operating PartnerPrime Movers LabTulsa, Ok, Us -
Vp Corporate DevelopmentZafrens Mar 2024 - PresentSan Diego, California, Us -
Board MemberZafrens Jul 2023 - Mar 2024San Diego, California, UsZafrens is a company developing a massively parallel drug discovery platform.
-
Operating PartnerPrime Movers Lab Jan 2024 - PresentJackson, Wyoming, Us
-
PartnerPrime Movers Lab Sep 2022 - Jan 2024Jackson, Wyoming, UsPrime Movers Lab invests in breakthrough scientific startups founded by the world's prime movers – the inventors who transform billions of lives across energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture. PML is actively investing out of Fund 3, an early stage fund, and has $1.2B under management.We offer Prime Movers comprehensive resources and integrated coaching to support the transformation of world-class technical experts into extraordinary executives. Our team has developed in-depth academic scientific research, commercialized novel intellectual property, scaled significant enterprises, and mentored renowned scientists on their entrepreneurial journey.
-
Venture PartnerPrime Movers Lab May 2022 - Aug 2022Jackson, Wyoming, Us
-
Board MemberLygenesis Oct 2023 - PresentPittsburgh, Pennsylvania, UsLyGenesis is a clinical-stage startup pioneering the use of lymph nodes as living bioreactors to transform transplant medicine and expand the field of cell therapy for millions of patients. -
Board MemberIridia, Inc. Jan 2023 - PresentCarlsbad, California, UsIridia is storing the world of data in physical form using nature's building block, DNA. -
Board MemberMorphoceuticals, Inc. Jan 2023 - PresentMedford, Ma, UsMorphoceuticals is developing therapeutics modulating the “bio-electrome” to regrow human limbs, repair injuries, and treat rare congenital diseases and malformations based on the research of Drs. Michael Levin and David Kaplan. -
Venture PartnerAtento Capital May 2022 - Jul 2024Tulsa, Oklahoma, UsAtento Capital is an early stage venture capital firm and fund of funds based in Tulsa, OK, affiliated with the George Kaiser Family Foundation (GKFF). As VP, supported diligence and post-investment portfolio management and CEO advising in the areas of life sciences, agriculture, materials sciences, and deep tech. -
Board MemberGilgamesh Pharmaceuticals Oct 2023 - May 2024New York, New York, UsGilgamesh is a clinical-stage company developing safer, more beneficial molecules at the forefront of psychedelic medicine. -
Board MemberIviva Medical Inc Jan 2023 - Mar 2024Woburn, Massachusetts, Us -
Board ObserverDimension Inx Jan 2023 - Mar 2024Chicago, Illinois, UsDimension inx manufactures the substrates for life for use as tissue therapeutics, including 3D printed bone grafts, soft tissue replacements, and injectable bioscaffolds. -
Board MemberElevian, Inc. Oct 2022 - Mar 2024Newton, Massachusetts, Us -
Portfolio DirectorAntiverse Apr 2022 - Sep 2022Cardiff, Wales, GbAntiverse uses machine learning to discover, optimize and accelerate the creation of new biologic medicines. The company combines antibody discovery, bioinformatics, next generation sequencing, deep learning and other advanced computational techniques to generate novel functional antibodies for the treatment of disease. The company can begin from a blank page, a full NGS dataset, or discarded data to develop functional binders to the desired target. The biotechnology industry has been trial-and-error for decades. Tight integration between wet lab, dry lab, and automating the interface between them, means that the future of biologics discovery finally can be better, faster and cheaper. I'm excited to accelerate Antiverse on their roadmap to 100 antibody programs in development.Contact bd@antiverse.io to learn about the future of antibody-based drug discovery. -
AdvisorAntiverse Aug 2021 - Mar 2022Cardiff, Wales, Gb
-
General PartnerTomorrowscale Ventures Nov 2021 - Sep 2022TomorrowScale Ventures is an early stage venture capital fund backing deep technology and life science companies across the United States and Europe, targeting exceptional scientific and technical founding teams tacking challenges with huge impact with which to partner and support from insight to exit velocity, and beyond.
-
Founder & HostTomorrowscale Jun 2019 - Sep 2022A podcast series consisting of conversations with the scientists and entrepreneurs who are building the future. TomorrowScale is a passion project that I created to tell stories from the forefront of scientific endeavor.
-
Senior Director, Drug DevelopmentTetherex Pharmaceuticals Apr 2018 - Mar 2022Tetherex Pharmaceuticals is a clinical-stage drug development company founded to develop novel first-in-class biologic therapeutics in inflammatory and oncologic diseases. The Company recently completed Phase IIa trials in asthma and COPD with lead program SelK2, a functionally blocking anti-PSGL-1 monoclonal antibody. Its mechanism is to reduce the infiltration of activated T cells into the lung tissue in patients with severe chronic inflammation. The compound has been tested as safe in over 150 subjects to date. Additional inflammatory and oncology-related indications are envisioned.Tetherex is also completing an open-label Phase Ia/Ib study of the first single-cycle vectored vaccine, SC-Ad6-1 for the prevention of SARS-CoV-2 infection via intramuscular and intranasal administration. Single-cycle adenovirus vectored vaccines amplify the transgene (Spike protein), but do not permit replication. A self-amplifying vaccine has the potential for enabling intranasal dosing, reduced manufacturing costs, improved safety, and enhanced potency. It was a privilege to work with Dr. Scott Rollins (Alexion co-founder, Selexys CEO) and Dr. Russell Rother (former Alexion CSO and Selexys COO) and rest of the incredible team at Tetherex to conduct rapid biologics development, 10x scale-up, tackle a vaccine from vial-to-trial, and conduct 4 clinical trials in as many years across 8 countries and 3 continent amidst the challenges of a global pandemic.
-
Venture PartnerDeep Science Ventures Jul 2021 - Dec 2021London, GbDeep Science Ventures synthesizes knowledge, talent and capital into optimal scientific ventures. DSV is a novel thesis-driven model where scientists, engineers, and entrepreneurs architect impactful ventures from first principles to redefine entire industries. -
PrincipalBriggsbio Oct 2017 - Jul 2021Strategic advisor to the life sciences and high technology industries. Dedicated to helping pharmaceutical, biotechnology, diagnostics, medical device, nanotechnology, robotics, and other high technology companies develop and commercialize next generation products and companies. Capabilities: - Venture creation and technology development - Business and technology development strategy - Corporate development and partnering - Market research and commercialization strategy - IP strategy and development - Clinical and regulatory affairs - Project management - Capital formation and investor relations
-
Founder, InventorSnaplab Technologies Jan 2014 - Jan 2018Automation and AI for geology and drilling applications. High-throughput robotics and computer vision platform driven by AI and predictive analytics for the oil & gas industry.
-
Vice President, Business Development & OperationsAccele Biopharma, Inc. Jun 2014 - Oct 2017Accele Biopharma and Accele Venture Partners, a related special purpose venture fund, were formed to create a capital-efficient mechanism to identify, finance and manage groundbreaking early stage life science technologies that have the potential to dramatically improve human healthcare, have strong commercial promise, and have the potential for generating early proof of concept data. I served as VP Business Development and Operations, and Venture Associate until the closure of AVP. Our portfolio included: - Otologic Pharmaceutics (Autigen; small molecules and siRNA LNPs for the treatment of hearing loss, hearing regeneration, tinnitus) - Pamlico BioPharma (Fully human monoclonal antibodies for infectious disease & cancer; Preclinical) - Synereca Pharmaceuticals (Antibiotic potentiation for resistant Gram-Negative infections; Preclinical)- Jortan Pharmaceuticals (Picomilar BACE2 inhibitors targeting beta cell regeneration for diabetes) -
Founder, CeoChorus Labs Oct 2012 - Nov 2015Oklahoma City, Ok, UsCreators of Baton, an intelligent productivity application. Acquired in 2015. -
Corporate Development And OperationsAltheus Therapeutics, Inc. Jun 2007 - May 2014Oklahoma City, Ok, UsI joined Altheus as the company's first hire, right out of my undergraduate biochemistry degree. During my seven years at Altheus I was given the opportunity to learn and grow across all aspects of a startup biopharmaceutical development company in increasing capacities, learning from a fantastic C-suite along the way. Activities included: building a cGMP manufacturing facility from scratch, hydrogel and oral formulation development, preclinical/non-clinical/clinical development and regulatory development, operations, business development, and investor relations. Altheus raised nearly $17 million and was the first Oklahoma-based company to conduct a Phase 2 clinical trial. -
ChairmanOklahoma Bioscience Roundtable Jan 2013 - Dec 2013
-
Alumni Team LeaderCenter For The Creation Of Economic Wealth Jan 2007 - Dec 2007
Justin Briggs Skills
Justin Briggs Education Details
-
University Of OklahomaBusiness -
Oklahoma City UniversityBusiness Administration
Frequently Asked Questions about Justin Briggs
What company does Justin Briggs work for?
Justin Briggs works for Prime Movers Lab
What is Justin Briggs's role at the current company?
Justin Briggs's current role is Operating Partner.
What is Justin Briggs's email address?
Justin Briggs's email address is br****@****ail.com
What is Justin Briggs's direct phone number?
Justin Briggs's direct phone number is +140531*****
What schools did Justin Briggs attend?
Justin Briggs attended University Of Oklahoma, Oklahoma City University.
What skills is Justin Briggs known for?
Justin Briggs has skills like Biotechnology, Commercialization, Entrepreneurship, Clinical Development, Start Ups, Life Sciences, Pharmaceutical Industry, Regulatory Affairs, Lifesciences, Business Development, Strategic Planning, Technology Transfer.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial